	nticoa w.novacare	407	'5 Walke	Ser\ er Rd, Suit ker Plaza)	te 3A		6.030
Patient Information and	Rel				S		
Name: DOB: HCN: Address: Phone Number:		LMWH Dos Recent Labs	ing	INR	BUN	Dose	
Medical Conditions: Other Medications:		Bridge patient with: Innohep/Lovenox/Fragmin units/mg daily/bid until: a) therapeutic INR x 2 days (minimum 5 days overlap) b) other					
Anticoagulation Strateg	y (ME	) to c	circl	e or	WI	rite in)	

○ Hospital Discharge Authorization - 1 month maximum. Further authorization by outpatient physician only. ○ Ambulatory Care Authorization - Authorization extends for the treatment duration indicated below.

Indication	INR Target	Duration	Alternative INR Target & Duration		
DVT/PE         First event/reversible cause         First event/idiopathic         First event with cancer, or         hypercoagulable state         Recurrent DVT/PE         Atrial Fibrillation         Cardiomyopathy         Acute Myocardial Infarction	2-3	3 months 6 months 12 months – Life 12 months - Life Life Life 3 months		<-The chart provides options for warfarin therapy based on the suggestions made by the writers of the CHEST guidelines for antithrombotic therapy. CHEST 2012; 141(2 Suppl).	
Vascular Reconstruction		Life		<ul> <li>For subtherapeutic</li> <li>INRs bridge with</li> </ul>	
Valve Replacement MVR – mechanical MVR – bioprosthetic AVR – bioprosthetic Other: Other:	2.5-3.5 2-3 2.0-3.0 2-3	Life 3 months Life 3 months		LMWH? YES * NO at INR <	

Notes:

Physician Information	
Name/License Number:         Fax Number:         Phone Number:         Ext:	Addressograph
Signature	
y signature, I understand that my patient will be dosed on Warfarin and/or LMWH by the clinical pharmacist at Novacare Pharmacy, according to established policies and J nacist may schedule appropriate laboratory draws and anticoagulation visits according to the patient's need within the guidelines of Novacare Pharmacy' policies and proceed for the purpose of collecting the required aliquot of blood for POC INR testing. The referring physician is still responsible for the patient. The clinical pharmacists are wor refauthorize that the pharmacist carry out a comprehensive medication review (AKA MedsCheck and Follow-up MedsCheck) and evaluation/management (aka Clinical Con- ctions, as stipulated in Novacare Pharmacy's Anticoagulation Policies and Procedures.	tures. Additionally, I delegate to the pharmacist the responsibility of lancing my pa king under the supervision/delegation of the referring physician. By my signature,